FFish Do you have any new AMRN TA analysis on APPROXIMATELY when FOMO and/or Super Vocano will explode to keep SP above $5 consistently? I've been hoping for JUST FOMO (no Super Vocano) to keep SP above $5.xx+ since after 11/5 Q3 ER due to the followings:
1) Stifel 2020 Virtual Healthcare conference on Monday, November 16, 2020 at 8:40 a.m. Eastern Time (ET)
2) Jefferies Virtual London Healthcare conference on Thursday, November 19, 2020 at 9:40 a.m. Eastern Time (ET)
3)Nov. 13, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT® CABG at American Heart Association’s (AHA) Virtual Scientific Sessions 2020
4)11/18 Featured Amarin-supported data presented at AHA Virtual Scientific Sessions 2020 included:
a) “Eicosapentaenoic Acid, but Not Docosahexaenoic Acid or a Mixed Omega-3 Fatty Acid Supplement, Inhibits Low-density Lipoprotein Oxidation in a Time-dependent Manner” – presented on behalf of all authors by Samuel Sherratt, B.S., Elucida Research, Beverly, MA
b) “Contrasting Effects of Phospholipid Linked Eicosapentaenoic Acid (EPA) and Arachidonic Acid (AA) on Membrane Structure and Stability” – presented on behalf of all authors by Samuel Sherratt, B.S., Elucida Research, Beverly, MA
c) “Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG” – presented on behalf of all authors by Subodh Verma, M.D., Ph.D., University of Toronto, Toronto, Ontario, Canada
d) “Consistent Cost-effectiveness of Icosapent Ethyl Across Patient Profiles From REDUCE-IT” – presented on behalf of all authors by Zugui Zhang, Ph.D., ChristianaCare Health System, Newark, DE
e) “Are the Results of Clinical Trials Relevant in the Real World? The Applicability of REDUCE-IT to the Fast-MI Registry” – presented on behalf of all authors by Jean Ferrières, M.D., M.Sc., Toulouse Rangueil University Hospital, Toulouse, France
5) Nov. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today shared positive, statistically significant top-line results from Protocol Number EDPC003R01, a Phase 3 clinical trial of VASCEPA® (icosapent ethyl) conducted in China by Amarin partner, Edding
6)Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Healthcare Conference (Virtual) taking place from December 1 - December 3, 2020
7) Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a licensor against Hikma Pharmaceuticals PLC and Hikma’s U.S. affiliate
8) Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that scientific findings that add to the growing body of knowledge on VASCEPA® (icosapent ethyl) will be presented during the National Lipid Association (NLA) Scientific Sessions 2020, being held virtually from December 10 – 12, 2020
9) Dec. 12, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of clinical results from the CardioLink-9 Trial, the first results of a study of VASCEPA® (icosapent ethyl) in COVID-19 infected outpatients.
10) Dec 14, 2020 Late Breakers
a) “EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial” – presented on behalf of all authors by Michael Miller, M.D., University of Maryland Medical System, Baltimore, MD
b) “REDUCE-IT USA: Results from the 3146 Patients Randomized in the United States” – presented on behalf of all authors by Michael Miller, M.D., University of Maryland Medical System, Baltimore, MD
c) “Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability and Changes Fatty Acid Content in a Manner Distinct from Docosahexaenoic Acid” – presented on behalf of all authors by R. Preston Mason, Ph.D., Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Elucida Research LLC, Beverly, MA
d) “Eicosapentaenoic acid Reduces Expression of Pulmonary Endothelial Angiotensin Converting Enzyme (ACE) Linked to Inflammation” – presented on behalf of all authors by R. Preston Mason, Ph.D., Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Elucida Research LLC, Beverly, MA
e) “Eicosapentaenoic Acid Reverses Endothelial Dysfunction following Exposure to the Cytokine IL-6 in Contrast to Docosahexaenoic and Arachidonic Acids” – presented on behalf of all authors by R. Preston Mason, Ph.D., Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Elucida Research LLC, Beverly, MA
f) “Icosapent Ethyl Mitigates Dyslipidemia by Both Hastening LDL Clearance and Slowing Triglyceride-Rich Lipoprotein Production” – presented on behalf of all authors by Richard Dunbar, M.D., formerly of the Perelman School of Medicine, University of Pennsylvania, and currently senior director, clinical development, Amarin.
g) “First Human Trial of a Loading Dose of Icosapent Ethyl in Patients with COVID-19: Primary Results of the VASCEPA COVID-19 CardioLink-9 Randomized Trial” – presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (as described in a separate press release dated December 12, 2020 and related FAQ on Amarin’s website)
I'm EXHAUSTED following so many AMRN GOOD news/PRs in just a little more than 1 month and no FOMO is on the horizon YET. And...I'm still holding my 50K share HEAVY BAG.LOL=)
